ProCE Banner Activity

Managing AEs With Enfortumab Vedotin: A Patient Case Example

Case Challenge
Multimedia
Listen as Susan K. Roethke, CRNP, MSN, AOCNP, ANP-BC, discusses optimal management of common AEs associated with enfortumab vedotin treatment in patients with advanced or metastatic urothelial carcinoma.

Released: December 22, 2020

Expiration: December 21, 2021

No longer available for credit.

Share

Faculty

Susan Roethke

Susan Roethke, CRNP, MSN, AOCN, ANP-BC

Nurse Practitioner
Department of Hematology/Oncology
Genitourinary Medical Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Astellas Seattle Genetics

Janssen administered by Scientific Affairs

Learning Objectives

  • Plan therapy for patients with urothelial carcinoma and disease progression during or following platinum-containing chemotherapy and/or immune checkpoint inhibitor therapy
  • Describe to patients and colleagues the available data and unique mechanisms of action of novel targeted therapies for the treatment of advanced urothelial carcinoma
  • Evaluate the toxicity profile as well as the pharmacokinetics and exposure-response association of approved antibody–drug conjugates in urothelial carcinoma

Faculty Disclosure

Primary Author

Susan Roethke, CRNP, MSN, AOCN, ANP-BC

Nurse Practitioner
Department of Hematology/Oncology
Genitourinary Medical Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Susan K Roethke, CRNP, MSN, AOCNP, ANP-BC, has disclosed that she has received fees for non-CME/CE services from Astellas and Pfizer.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has disclosed that his spouse/partner has received salary from AstraZeneca and has ownership interest in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen M. Rosenthal, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.